[Skip to Navigation]
August 18, 2008

The Use of Patch Tests in Determining Hypersensitivity to Etanercept and Infliximab

Arch Dermatol. 2008;144(8):1070-1071. doi:10.1001/archderm.144.8.1070-b

With great interest, we read the article by Seneschal et al1 describing 8 patients who experienced psoriasiform eruptions during anti–tumor necrosis factor therapy. These patients were patch tested with the European standard series and 2 anti–tumor necrosis factor molecules. One patient who had developed adalimumab-related psoriasiform plaques responded to the etanercept patch test with edema and vesicles after 48 hours. Day 8 readings showed a flare of dermatitis in half the patients.1,2